Company intelligence / Profile preview

Novosis

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Novosis is a South Korean biotechnology company specializing in regenerative medicine and bone tissue engineering. The company is best known for its flagship product, also named Novosis, which is a recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) delivered via a hydroxyapatite carrier. This technology is designed to stimulate bone formation in patients undergoing spinal fusion, dental implants, or treatment for complex fractures. Operating as a subsidiary of CGBio, Novosis is actively expanding its presence in global markets and is currently pursuing FDA approval for its bone graft products in the United States.

Therapeutic areas: RheumatologyOther
Modalities: Recombinant proteinBiologic
Industry: Biotech

Drug pipeline

1 asset

leuprorelin

Partnerships

Daewoong PharmaceuticalCGBio

Beyond the preview

Go deeper on Novosis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novosis.